Under the terms of the agreement, Sosei Heptares will receive an upfront payment of $100 million and will be eligible for up to $2.6 billion in potential milestone payments. It will also receive tiered sales royalties ranging from high single-digit to mid-teen percentage on the future sales of any products developed under the partnership, the companies said.
Neurocrine Biosciences will obtain development and commercialization rights to a portfolio of clinical and preclinical compounds discovered by Sosei Heptares as potential treatments for neurological disorders.
For the most advanced program, HTL-0016878, Neurocrine Biosciences plans to submit an investigational new drug application and launch a placebo-controlled phase 2 study as a potential treatment for schizophrenia in 2022, the company said.
Under the agreement, Sosei Heptares has retained the right to develop compounds in Japan in all indications, while Neurocrine Biosciences will receive co-development and profit share options.
Price: 86.15, Change: +0.13, Percent Change: +0.15
|Li-Cycle Holdings Fiscal Q4 Loss Widens; Revenue Inc...|
|-- Earnings Flash (LYTS) LSI INDUSTRIES Posts Q2 EPS...|
|-- Earnings Flash (LYTS) LSI INDUSTRIES Reports Q2 R...|
|Mizuho Securities Starts Mondelez International at B...|
|-- Earnings Flash (EXP) EAGLE MATERIALS Posts Q3 Rev...|